Pyk2-IN-2 (compound 13j) acts as a Pyk2 inhibitor, exhibiting an IC 50 value of 0.608 μM for FAK kinase [1].

Pyk2-IN-2 (compound 13j) has an IC₅₀ value of 55 nM against PYK2 cells [1].

The HLM blood clearance rate of Pyk2-IN-2 (compound 13j) is 31 mL/min/kg [1]. In pharmacokinetic studies on male Wistar-Han rats [1], the following data was observed: For intravenous administration at a dose of 1 mg/kg, the half-life (t 1/2) was 2.0 hours, plasma clearance (Cl p) was 2.0 mL/min/kg, and steady-state volume of distribution (Vd ss) was 0.15 L/kg. For the oral administration at a dose of 30 mg/kg, the maximum concentration (C max) was 61324 nM, calculated free maximum concentration (Calc C max free) was 184 nM, with a bioavailability (%F) of 47, and plasma protein binding (PPB, fu) of 0.003.